Study Details

PROTOCOL SUMMARY

The primary objective of this study is to assess overall survival (OS) with sacituzumab govitecan-hziy in comparison with treatment of physician's choice (TPC) in participants with metastatic or locally advanced unresectable urothelial cancer (UC).

Participation Requirements

Age

18 Years +

Sex

All

Healthy Volunteers

Medical Condition

Locally Advanced or Metastatic Unresectable Urothelial Cancer

Gender

N/A

Date

January 2021 - October 2024

Study Type

Interventional

Study Phase

Phase 3

Product

Sacituzumab Govitecan-hziy, Paclitaxel, Docetaxel, Vinflunine

Eligibility Information

Inclusion Criteria

Individuals with histologically documented metastatic or locally advanced unresectable UC defined as
Tumor (T) 4b, any node (N) or
Any T, N 2-3 Tumors of upper and lower urinary tract are permitted. Mixed histologic types are allowed if urothelial is the predominant histology.
Eastern Cooperative Oncology Group (ECOG) performance status (PS) score of 0 or 1.
Individuals with progression or recurrence following receipt of platinum-containing regimen and anti programmed cell death protein 1/programmed death-ligand 1 (PD-1/PD-L1) therapy for metastatic or locally advanced unresectable disease will be enrolled.
a. Individuals with recurrence or progression ≤12 months following completion of cisplatin-containing chemotherapy given in the neo-adjuvant/adjuvant setting may utilize that line of therapy to be eligible for the study. The 12-month period is counted from completion of surgical intervention or platinum therapy, respectively. These individuals must receive anti PD-1/PD-L1 therapy in the metastatic or locally advanced unresectable setting to be eligible.
b. Individuals who received either carboplatin or anti PD-1/PD-L1 therapy in the neo- adjuvant/adjuvant setting will not be able to count that line of therapy towards eligibility for the study.
c. Cisplatin ineligible individuals who meet one of the below criteria and who were treated with carboplatin in the metastatic or locally advanced unresectable settings may count that line of therapy towards eligibility. They must then have received anti PD-1/PD-L1 therapy in metastatic or locally advanced unresectable setting to be eligible for the study.
Cisplatin ineligibility is defined as meeting one of the following criteria:
1. Creatinine Clearance < 60 mL/min
2. Grade ≥ 2 Audiometric Hearing Loss
3. Grade ≥ 2 Peripheral Neuropathy
4. New York Heart Association (NYHA) Class III heart failure
5. ECOG PS ≥ 2
d. Anti PD-1/PD-L1 therapy administered as part of maintenance therapy may be counted towards eligibility for the study
e. Individuals who have progressed after receiving enfortumab vedotin in prior lines of therapy, and individuals who are either ineligible or unable to tolerate enfortumab vedotin therapy, are eligible to enroll in the study
f. Individuals who received only concurrent chemoradiation for bladder preservation without further systemic therapy are not eligible to enroll in the study. The substitution of carboplatin for cisplatin does not constitute a new regimen provided no new chemotherapeutic agents were added to the regimen and no progression was noted prior to the change in platinum.
Individuals with previously treated brain metastases may participate in the study provided they have stable CNS disease for at least 4 weeks prior to the first dose of study drug and stabilization of all neurologic symptoms, have no evidence of new or enlarging brain metastases, and are not using steroids >20 mg of prednisone (or equivalent) daily for brain metastases for at least 7 days prior to first dose of the study drug.
Adequate hematologic counts without transfusion or growth factor support within 2 weeks of study drug initiation (hemoglobin ≥ 9 g/dL, absolute neutrophil count (ANC) ≥1,500/mm^3, and platelets ≥100,000/µL).
Adequate hepatic function (bilirubin ≤1.5x institutional upper limit of normal (IULN), aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5 x IULN or ≤ 5 x IULN if known liver metastases and serum albumin >3 g/dL).
Docetaxel will only be option in TPC arm for Individuals with a total bilirubin ≤1 x IULN, and an AST and/or ALT ≤1.5x IULN if alkaline phosphatase is also >2.5 x IULN.
Creatinine clearance ≥30 mL/min as assessed by the Cockcroft-Gault equation or other validated instruments (e.g. Modification of Diet in Renal Disease (MDRD) equation).
Females of childbearing potential must have a negative urine or serum pregnancy test within 72 hours prior to receiving the first dose of study drug. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required.
Females of childbearing potential must be willing to use 2 methods of birth control or be surgically sterile or abstain from heterosexual activity for the course of the study through 6 months after the last dose of study drug. Individuals of childbearing potential are those who have not been surgically sterilized or have not been free from menses for >2 years.
Males must agree to use an adequate method of contraception starting with the first dose of study therapy through 6 months after the last dose of study therapy.

Exclusion Criteria

Females who are pregnant or lactating.
Have had a prior anti-cancer monoclonal antibody (mAb)/ antibody-drug conjugate (ADC) within 4 weeks prior to Cycle 1 Day 1 (C1D1) or have had prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to C1D1. Individuals participating in observational studies are eligible.
Have received prior chemotherapy for UC with any available SOC therapies in the control arm (i.e., both prior paclitaxel and docetaxel in regions where vinflunine is not an approved therapy, or prior paclitaxel, docetaxel and vinflunine in regions where vinflunine is approved and is commercially available).
Have not recovered (i.e., ≤ Grade 1) from AEs due to previously administered chemotherapeutic agent.
Note: Individuals with ≤ Grade 2 neuropathy or any grade of alopecia are an exception to this criterion and will qualify for the study.
Note: If Individuals received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting study therapy.
Have previously received topoisomerase 1 inhibitors.
Have an active second malignancy.
• Note: Individuals with a history of malignancy that have been completely treated and with no evidence of active cancer for 3 years prior to enrollment, or individuals with surgically cured tumors with low risk of recurrence are allowed to enroll in the study after discussion with the medical monitor.
Have active cardiac disease, defined as:
Myocardial infarction or unstable angina pectoris within 6 months of C1D1.
History of serious ventricular arrhythmia (i.e., ventricular tachycardia or ventricular fibrillation), high-grade atrioventricular block, or other cardiac arrhythmias requiring anti-arrhythmic medications (except for atrial fibrillation that is well controlled with antiarrhythmic medication); history of QT interval prolongation.
NYHA Class III or greater congestive heart failure or left ventricular ejection fraction of <40%.
Have active chronic inflammatory bowel disease (ulcerative colitis, Crohn's disease) or gastrointestinal (GI) perforation within 6 months of enrollment.
Have an active serious infection requiring anti-infective therapy (Contact medical monitor for clarification).
Have known history of Human Immunodeficiency Virus (HIV)-1/2 with undetectable viral load and on medications that may interfere with SN-38 metabolism.
Have active Hepatitis B Virus (HBV) or Hepatitis C Virus (HCV). In individuals with a history of HBV or HCV, individuals with a detectable viral load will be excluded.
Have other concurrent medical or psychiatric conditions that, in the investigator's opinion, may be likely to confound study interpretation or prevent completion of study procedures and follow-up examinations.
Have inability to tolerate or are allergic to any potential TPC agent or sacituzumab govitecan-hziy or unable or unwilling to receive the doses specified in the protocol.
Have inability to complete all specified study procedures for any reason.
Note: Other protocol defined Inclusion/Exclusion criteria may apply.

Locations

Locations (234)

Mayo Clinic - Arizona

Phoenix, Arizona, United States, 85054

UCLA Hematology/ Oncology

Los Angeles, California, United States, 90095

University of California Irvine (UCIMC)

Orange, California, United States, 92868

MedStar Washington Hospital Center

Washington, District of Columbia, United States, 20010

Baptist MD Anderson Cancer Center

Jacksonville, Florida, United States, 32207

Boca Raton Clinical Research Global USA - Plantation

Plantation, Florida, United States, 33322

University of Iowa Hospitals and Clinics

Iowa City, Iowa, United States, 52242

University of Maryland School of Medicine

Baltimore, Maryland, United States, 21201

Beth Israel Deaconess Medical Center

Boston, Massachusetts, United States, 02215

Montefiore Medical Center

Bronx, New York, United States, 10467

Roswell Park Cancer Institute

Buffalo, New York, United States, 14263

Weill Cornell Medical College

New York, New York, United States, 10065

Cleveland Clinic

Cleveland, Ohio, United States, 44195

Oklahoma Cancer Specialists and Research Institute (OCSRI)

Tulsa, Oklahoma, United States, 74104

Penn State Hershey Cancer Institute

Hershey, Pennsylvania, United States, 17033

Thompson Oncology Group - Knoxville Downtown

Knoxville, Tennessee, United States, 37916

University Cancer Specialists - Knoxville

Knoxville, Tennessee, United States, 37920

Harold C. Simmons Comprehensive Cancer Center

Dallas, Texas, United States, 75390

Center for Cancer and Blood Disorders

Fort Worth, Texas, United States, 76104

Seattle Cancer Care Alliance (SCCA)

Seattle, Washington, United States, 98109

Summit Cancer Centers

Spokane, Washington, United States, 99208

Chris O'Brien Lifehouse

North Ryde, New South Wales, Australia, 2109

Calvary Mater Newcastle

Waratah, New South Wales, Australia, 2298

Westmead Hospital

Westmead, New South Wales, Australia, 2145

Icon Cancer Centre Wesley

Auchenflower, Queensland, Australia, 4066

Southern Adelaide Local Health Network Incorporated

Bedford Park, South Australia, Australia, 5042

Ashford Cancer Centre Research - ICON Cancer Centre Adelaide

Kurralta Park, South Australia, Australia, 5037

ICON Cancer Centre Hobart

Hobart, Tasmania, Australia, 7001

Monash Health

Clayton, Victoria, Australia, 3168

Austin Health

Heidelberg, Victoria, Australia, 3084

Peter MacCallum Cancer Centre

Melbourne, Victoria, Australia, 3000

Sunshine Hospital

Saint Albans, Victoria, Australia, 3021

Liverpool Hospital

Nedlands, Western Australia, Australia, 6009

Sir Charles Gairdner Hospital

Nedlands, Western Australia, Australia, 6009

Universitätsklinik für Innere Medizin Graz

Graz, Austria, 8036

Ordensklinikum Linz GmbH Barmherzige Schwestern

Linz, Austria, 4010

Krankenhaus Der Barmherzigen Bruder Wien

Wien, Austria, 1020

Grand Hôpital De Charleroi - Notre Dame

Charleroi, Belgium, 6000

Az Maria Middelares Ghent

Gent, Belgium, 9000

Universitair Ziekenhuis Gent

Gent, Belgium, 9000

Universitair Ziekenhuis Leuven

Leuven, Belgium, 3000

Centre Hospitalier Universitaire de Liège

Liège, Belgium, B-4000

Multiprofile Hospital for Active Treatment Heart and Brain EAD

Pleven, Bulgaria, 5800

Specialized Hospital for Active Treatment of Oncological Diseases - Sofia District

Sofia, Bulgaria, 1233

Cross Cancer Institute

Edmonton, Canada, T6G 1Z2

qeii health sciences centre - VG site

Halifax, Canada, B3H 2Y9

Juravinski Hospital and Cancer Centre

Hamilton, Canada, L8V 5C2

London Health Sciences Centre

London, Canada, N6A 4G5

Jewish General Hospital

Montréal, Canada, H3T 1E2

McGill University Health Centre

Montréal, Canada, H4A 3J1

R.S. McLaughlin Durham Regional Cancer Centre

Oshawa, Canada, L1G 2B9

Princess Margaret Cancer Centre

Toronto, Canada, M5G 2M9

British Columbia Cancer Agency-Vancouver Centre

Vancouver, Canada, V5Z 4E6

Peking University First Hospital

Beijing, China, 100034

Chinese People's Liberation Army General Hospital - 301 Hospital

Beijing, China, 100039

Beijing Cancer Hospital

Beijing, China, 100142

Chinese Academy of Medical Sciences Cancer Hospital

Beijing, China, 100730

1st Hospital Jilin University

Changchun, China, 130021

Hunan Cancer Hospital - Xiangya Hospital - Central South University

Changsha, China, 410013

West China Hospital Sichuan University

Chengdu, China, 610041

Sichuan Academy of Medical Sciences & Sichuan Provincial People's Hospital

Chengdu, China, 610072

Chongqing University Cancer Hospital

Chongqing, China, 400030

The First Affiliated Hospital of Fujian Medical University

Fujian, China, 350005

Union Hospital of Fujian Medical University

Fuzhou, China, 350001

Sun Yat-Sen University Cancer Center

Guangzhou, China, 510060

Zhejiang Provincial People's Hospital - Zhaohui

Hangzhou, China, 310014

Cancer Hospital of the University of Chinese Academy of Sciences Zhejiang Cancer Hospital

Hangzhou, China, 310022

Anhui Provincial Cancer Hospital

Hefei, China, 230031

Qilu Hospital of Shandong University

Jinan, China, 250012

The First Affiliated Hospital of Nanchang University

Nanchang, China, 330006

Nanjing Drum Tower Hospital

Nanjing, China, 210008

Liaoning Cancer Hospital and Institute

Shenyang, China, 110042

Tianjin Medical University Cancer Institute & Hospital

Tianjin, China, 300060

Affiliated Tumor Hospital of Xinjiang Medical University

Urumqi, China, 830000

The First Affiliated Hospital of Wenzhou Medical University

Wenzhou, China, 325000

Union Hospital Tongji Medical College Huazhong University of Science and Technology

Wuhan, China, 430030

Clinical Hospital Centre Split

Split, Croatia, 21000

Clinical Hospital Centre "Sestre Milosrdnice"

Zagreb, Croatia, 10000

University Hospital Centre Zagreb

Zagreb, Croatia

Fakultni nemocnice Olomouc

Olomouc, Czechia, 775 20

Urocentrum Praha

Praha 2, Czechia, 120 00

Ramsay Health Clinic Belharra

Bayonne, France

CHU Saint Andre

Bordeaux, France, 33075

Centre Hospiltalier Universitaire Brest - Hôpital Morvan

Brest, France, 29200

Centre Francois Baclesse

Caen Cedex 5, France, 14076

Centre Jean Perrin

Clermont-Ferrand, France, 63011

Centre Georges- Francois Leclerc

Dijon, France, 21000

Centre Hospitalier Departemental Vendee

La Roche-Sur-Yon Cedex, France, 85925 CEDEX 9

Centre Oscar Lambret

Lille, France, 59000

Centre Leon Berard

Lyon, France, 69373

Institut Régional du Cancer de Montpellier ICM Val d' Aurelle

Montpellier, France, 34090

Centre Antoine Lacassagne

Nice Cedex 2, France, 06189

Centre Hospitalier Universitaire de Nimes

Nimes, France, 30029

Hôpital Européen Georges-Pompidou

Paris, France, 75015

Centre Eugene Marquis

Rennes Cedex, France, 35042

Centre Hospitalier Privé Saint-Grégoire

Saint-Grégoire, France, 35760

Les Hôpitaux Universitaires de Strasbourg

Strasbourg cedex, France, 67091

Hôpital Foch

Suresnes, France, 92150

Institut Claudius Regaud

Toulouse Cedex 9, France, 31059

Institut Gustave Roussy

Villejuif Cedex, France, 94805

High Technology Hospital MedCenter

Batumi, Georgia, 6000

New Hospitals

Tbilisi, Georgia, 0114

L. Managadze National Center of Urology

Tbilisi, Georgia, 0144

Evex Medical corporation

Tbilisi, Georgia, 0160

Jerarsi Clinic

Tbilisi, Georgia, 0167

Universitatsklinik Dresden

Dresden, Germany, 01307

Malteser Waldkrankenhaus Erlangen

Erlangen, Germany, 91054

Universitätsklinikum Essen

Essen, Germany, 45147

Centrum fur Hamatologie und Onkologie Bethanien

Frankfurt/Main, Germany, 60389

Asklepios Klinik Altona

Hamburg, Germany, 22763

Institut Für Versorgungsforschung in Der Onkologie

Koblenz, Germany, 56068

Universitatsklinikum Munster

Münster, Germany, 48149

Studienpraxis Urologie

Nürtingen, Germany, 72622

Universitätsklinikum Tübingen

Tübingen, Germany, 72076

Charité Universitätsmedizin Berlin - Campus Benjamin Franklin

Wien, Germany, 1100

401 General Military Hospital of Athens

Athens, Greece, 115 25

Henry Dunant Hospital

Athens, Greece, 115 26

Alexandra General Hospital

Athens, Greece, 11528

Attikon Hospital

Chaidari, Greece, 124 62

Regional University General Hospital of Herakleio, Crete

Herakleio, Greece, 81352

University Hospital Of Ioannina

Ioannina, Greece, 45332

University Hospital of Larissa

Larisa, Greece, 413 34

Athens Medical Center

Maroussi, Greece, 151 25

University Hospital of Patras

Patra, Greece, 26332

Bioclinic - Thessaloniki

Thessaloniki, Greece, 546 22

Theagenio Anticancer Hospital of Thessaloniki

Thessaloniki, Greece, 546 39

Anassa General Clinic

Thessaloniki, Greece, 54623

Interbalkan Medical Center of Thessaloniki

Thessaloniki, Greece, 555 35

Prince of Wales Hospital

Hong Kong, Hong Kong, 0

Queen Mary Hospital

Hong Kong, Hong Kong

Hong Kong United Oncology Centre

Kowloon, Hong Kong

Tallaght University Hospital

Dublin, Ireland, D24 NR0A

University Hospital Waterford

Waterford, Ireland, X91 ER8E

Shamir Medical Center (Assaf Harofeh)

Be'er Ya'akov, Israel, 7030000

Rambam Health Care Campus

Haifa, Israel, 3109601

Hadassah University Hospital Ein Kerem

Jerusalem, Israel, 91120

Meir Medical Center

Kfar-Sava, Israel, 44281

Rabin Medical Center

Petach Tikva, Israel, 4941492

Tel Aviv Medical Center (Ichilov Hospital)

Tel Aviv, Israel, 6423906

Chaim Sheba Medical Center

Tel Hashomer, Israel, 52621

Ospedale San Donato

Arezzo, Italy, 52100

Centro di Riferimento Oncologico di Aviano

Aviano, Italy, 33081

Istituto Tumori Bari Giovanni Paolo II - IRCCS

Bari, Italy, 70124

Istituto di Candiolo - Fondazione del Piemonte per l'Oncologia

Candiolo (TO), Italy, 10060

Ospedale Policlinico San Martino

Genova, Italy, 16132

Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori

Meldola, Italy, 47014

Ospedale San Raffaele

Milan, Italy, 20132

Azienda Ospedaliero Universitaria Maggiore Della Carita

Novara, Italy, 28100

Azienda Ospedaliero Universitaria Pisana

Pisa, Italy, 56126

Istituto Regina Elena

Roma, Italy, 00144

Università Campus Bio-Medico di Roma

Rome, Italy, 00128

Ospedale Civile Di Sondrio

Sondrio, Italy, 23100

Azienda Ospedaliera Santa Maria di Terni

Terni, Italy, 05100

Azienda Ospedaliero-Universitaria San Luigi Gonzaga

Torino, Italy, 10043

Ospedale di Trento - Presidio Ospedaliero Santa Chiara

Trento, Italy, 38122

Azienda Ospedaliera Universitaria Integrata Verona

Verona, Italy, 37126

Pusan National University Hospital

Busan-si, Korea, Republic of, 49241

Chungbuk National University Hospital

Cheongju, Korea, Republic of, 361-711

Chungnam National University Hospital

Daejeon, Korea, Republic of, 35015

National Cancer Center

Goyang-si, Korea, Republic of, 10408

Pusan National University Yangsan Hospital

Gyeongsangnam-do, Korea, Republic of, 50612

Gachon University Gil Medical Center

Incheon, Korea, Republic of, 405-760

Seoul National University Bundang Hospital

Seongnam-si, Korea, Republic of, 13620

Seoul National University Hospital

Seoul, Korea, Republic of, 03080

Severance Hospital, Yonsei University Health System

Seoul, Korea, Republic of, 03722

Asan Medical Center

Seoul, Korea, Republic of, 05505

Samsung Medical Center

Seoul, Korea, Republic of, 06351

The Catholic University of Korea Seoul Saint Mary's Hospital

Seoul, Korea, Republic of, 137-040

The Catholic University of Korea Saint Vincent's Hospital

Suwon, Korea, Republic of, 16247

Hospital de Braga

Braga, Portugal, 4710-243

Unidade Local de Saúde da Guarda - Hospital Sousa Martins

Guarda, Portugal, 6300-858

Centro Hospitalar de Leiria - Hospital de Santo André

Leiria, Portugal, 2410-197

Centro Hospitalar de Lisboa Norte - Hospital de Santa Maria

Lisbon, Portugal, 1649-035

Instituto Portugues de Oncologia do Porto Francisco Gentil, E.P.E

Porto, Portugal

Centro Hospitalar de Tras-os-Montes e Alto Douro

Vila Real, Portugal, 5000

BRCR Medical Center, Inc

San Juan, Puerto Rico, 00907

National University Hospital

Singapore, Singapore, 119074

Icon Cancer Centre Farrer Park

Singapore, Singapore, 217562

Tan Tock Seng Hospital

Singapore, Singapore, 308433

Hospital del Mar - Parc de Salut

Barcelona, Spain, 08003

Hospital Universitari Vall D'Hebron

Barcelona, Spain, 08035

Hospital Clinic de Barcelona

Barcelona, Spain, 8036

Hospital Reina Sofia

Córdoba, Spain, 14004

Hospital General Universitario Gregorio Maranon

Madrid, Spain, 28007

Clínica Universidad de Navarra - Madrid

Madrid, Spain, 28027

MD Anderson Cancer Center

Madrid, Spain, 28033

Hospital Universitario Ramon y Cajal

Madrid, Spain, 28034

Hospital Universitario 12 de Octubre

Madrid, Spain, 28041

Hospital Universitario Puerta de Hierro de Majadahonda

Majadahonda, Spain, 28222

Hospital Sant Joan de Déu de Manresa

Manresa, Spain, 08243

Complexo Hospitalario de Ourense (CHOU)

Ourense, Spain, 32005

Clinica Universidad de Navarra

Pamplona, Spain, 31008

Hospital Universitario Marqués de Valdecilla

Santander, Spain, 39008

Hospital Universitario Virgen del Rocio

Sevilla, Spain, 41013

Álvaro Cunqueiro Hospital

Vigo, Spain, 36213

Länssjukhuset Ryhov

Jönköping, Sweden, 553 05

Universitetssjukhuset i Linköping

Linköping, Sweden, 581 85

Karolinska Universitetssjukhuset - Solna

Stockholm, Sweden, 171 76

University Hospital Basel

Basel, Switzerland, 4051

Istituto Oncologico Della Svizzera Italiana (IOSI)

Bellinzona, Switzerland, 6500

University of Bern

Bern, Switzerland, 3010

Hôpitaux Universitaires de Genève

Geneva, Switzerland, 1205

Universitaetsspital Zurich - Klinik fur Medizinische Onkologie und Hematologie

Zurich, Switzerland, 8091

Kaohsiung Veterans General Hospital

Kaohsiung, Taiwan, 813

Kaohsiung Chang Gung Memorial Hospital

Kaohsiung, Taiwan, 833

Taipei Tzu Chi General Hospital

New Taipei City, Taiwan, 231405

Chiayi Chang Gung Memorial Hospital

Puzi, Taiwan, 613

China Medical University Hospital

Taichung City, Taiwan, 40447

Taichung Veterans General Hospital

Taichung, Taiwan, Taiwan 407

National Cheng Kung University Hospital

Tainan, Taiwan, 70403

National Taiwan University Hospital

Taipei City, Taiwan, 100

Taipei Veterans General Hospital

Taipei City, Taiwan, 11217

Chang Gung Memorial Hospital - Linkou Branch

Taoyuan, Taiwan, 333

Hacettepe Universitesi Tip Fakultesi- Kanser Enstitusu

Ankara, Turkey, 6230

Trakya Universitesi Saglik Arastirma ve Uygulama Merkezi

Edirne, Turkey, 22030

Bagcilar Medipol Mega Universite Hastanesi

Istanbul, Turkey, 34214

Istanbul Acibadem University Maslak Hospital

Istanbul, Turkey, 34457

T.C. Saglik Bakanligi Goztepe Prof. Dr. Suleyman Yalcin Sehir Hastanesi

Istanbul, Turkey, 34722

Medical Park Izmır Hastanesi

İzmir, Turkey, 35575

Cebeci Hastanesi

Mamak, Turkey, 6620

VKV Amerikan Hastanesi Department of Oncology

Şişli, Turkey, 34365

University Hospitals Birmingham NHS Foundation Trust

Birmingham, United Kingdom, B15 2WB

Dorset County Hospital NHS Foundation Trust

Dorchester, United Kingdom, DT1 2JY

NHS Greater Glasgow and Clyde

Glasgow, United Kingdom, G12 0YN

Barts Health NHS Trust

London, United Kingdom, EC1A 7BE

Guys and Saint Thomas NHS Foundation Trust, Guy's Hospital

London, United Kingdom, SE1 9RT

Sarah Cannon Research Institute London

London, United Kingdom, W1G 6AD

The Christie NHS Foundation Trust

Manchester, United Kingdom, M20 4BX

East and North Hertfordshire NHS Trust

Middlesex, United Kingdom, HA6 2RN

Oxford University Hospitals NHS Foundation Trust

Oxford, United Kingdom, OX3 7LE

Swansea Bay University Health Board

Port Talbot, United Kingdom, SA12 7BR

Royal Preston Hospital

Preston, United Kingdom, PR2 9HT

The Royal Marsden NHS Foundation Trust

Surrey, United Kingdom, SM2 5PT

The Royal Wolverhampton NHS Trust

Wolverhampton, United Kingdom, WV10 0QP

Study of Sacituzumab Govitecan-hziy (IMMU-132) Versus Treatment of Physician's Choice in Participants With Metastatic or Locally Advanced Unresectable Urothelial Cancer (TROPiCS-04)

OVERVIEW